株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

慢性リンパ球性白血病(CLL):パイプライン製品の分析

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 192526
出版日 ページ情報 英文 791 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.47円で換算しております。
Back to Top
慢性リンパ球性白血病(CLL):パイプライン製品の分析 Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017
出版日: 2017年05月31日 ページ情報: 英文 791 Pages
概要

慢性リンパ球性白血病(CLL)は、骨髄の(リンパ球と呼ばれる)白血球で始まる癌の一種で、その後、血液を侵します。症状はゆっくり進行し、異常なあざ(血小板が少ない場合)、発熱、感染症の再発、食欲不振または早期の満腹感、体重減少などの症状が見られます。治療は、外科手術、放射線療法、化学療法、またはいくつかを併用して行われます。

当レポートでは、慢性リンパ球性白血病(CLL)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

慢性リンパ球性白血病(CLL)の概要

治療薬の開発

治療薬の評価

治療薬の開発に従事している企業

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9374IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 44, 51, 1, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 7, 10 and 7 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Chronic Lymphocytic Leukemia (CLL) - Overview
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development
  • Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
  • Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
  • Chronic Lymphocytic Leukemia (CLL) - Drug Profiles
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
  • Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ABL Bio Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Alvotech Iceland, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptose Biosciences Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma GmbH, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Humorigin Biotechnology Corp, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison China MediTech Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics Corp, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech LLC, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mesoblast Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pfizer Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by PIQUR Therapeutics AG, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Plexxikon Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Qurient Co Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Redx Pharma Plc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Rhizen Pharmaceuticals SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita SA, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by United BioPharma Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Xencor Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2017
  • Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top